Table 1.

Summary of Phase 2 Trials

Patient TypeNDuration of study (not including run-in period)Treatment arm/change in HbA1c from baselineReference
Type 2513 months• Inhaled insulin/0.7%12
• Subcutaneous insulin/0.7%
Type 2623 months• Oral agent/0.13%13
• Oral agent plus inhaled insulin/2.28%
Type 1703 months• Subcutaneous insulin (2–3 injections/day)/0.83%14
• Inhaled insulin plus subcutaneous insulin (once daily)/0.64%